Literature DB >> 8345981

Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants.

L R Bulkow1, R B Wainwright, G W Letson, S J Chang, J I Ward.   

Abstract

We compared the immunogenicity of the four available Haemophilus influenzae type b (Hib) conjugate vaccines in Alaska Native infants. Three of the vaccines, Hib oligosaccharide-CRM197 (HbOC), polyribosylribitol phosphate-diphtheria toxoid (PRP-D) and polyribosylribitol phosphate-tetanus toxoid (PRP-T), were given at 2, 4 and 6 months of age, and the PRP Neisseria meningitidis outer membrane protein (PRP-OMP) conjugate vaccine was given at 2 and 4 months of age. Enrollment was largely sequential by vaccine availability beginning with HbOC and ending with PRP-T. A total of 225 infants completed the full vaccination series. Groups of infants receiving the different vaccines did not differ significantly by sex, ethnicity, degree Alaska Native or age at vaccination. The only vaccine that induced a response with the first 2-month dose was PRP-OMP; 91% of infants had > or = 0.15 micrograms/ml and 57% had > or = 1.0 microgram/ml of anti-PRP antibody by 4 months of age. After two doses it also remained the most immunogenic. After the full three vaccine series, trials that requires cough of 21 days is excessively restrictive.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8345981     DOI: 10.1097/00006454-199306000-00006

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  13 in total

1.  Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in Southwestern Alaska.

Authors:  Henry C Baggett; Thomas W Hennessy; Lisa Bulkow; Sandra Romero-Steiner; Debra Hurlburt; Patricia Holder; Alan J Parkinson; Rosalyn J Singleton; Orin Levine; George M Carlone; Jay C Butler
Journal:  Clin Vaccine Immunol       Date:  2006-06

2.  Haemophilus influenzae: then and now.

Authors:  J Z Jordens; M P Slack
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

3.  Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.

Authors:  Nina Ekström; Heidi Ahman; Jouko Verho; Jukka Jokinen; Merja Väkeväinen; Terhi Kilpi; Helena Käyhty
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.

Authors:  S J Devi; W D Zollinger; P J Snoy; J Y Tai; P Costantini; F Norelli; R Rappuoli; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

5.  Avidity determinations for Haemophilus influenzae Type b anti-polyribosylribitol phosphate antibodies.

Authors:  Sandra Romero-Steiner; Patricia F Holder; Patricia Gomez de Leon; Willie Spear; Thomas W Hennessy; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

Review 6.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

7.  Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

Authors:  Andrew J Pollard; Kirsten P Perrett; Peter C Beverley
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

8.  Developing a vaccine for Haemophilus influenzae serotype a: Proceedings of a workshop.

Authors:  A D Cox; L Barreto; M Ulanova; M G Bruce; Rsw Tsang
Journal:  Can Commun Dis Rep       Date:  2017-05-04

Review 9.  Long Term Impact of Conjugate Vaccines on Haemophilus influenzae Meningitis: Narrative Review.

Authors:  Mary Paulina Elizabeth Slack
Journal:  Microorganisms       Date:  2021-04-21

Review 10.  Invasive Haemophilus influenzae Infections after 3 Decades of Hib Protein Conjugate Vaccine Use.

Authors:  M P E Slack; A W Cripps; K Grimwood; G A Mackenzie; M Ulanova
Journal:  Clin Microbiol Rev       Date:  2021-06-02       Impact factor: 50.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.